The couple tied the knot in December last year. Photo / Instagram
Melbourne model and fitness entrepreneur Steph Claire Smith has taken to Instagram to reveal she is expecting her first child with hubby Josh Miller.
The 25-year-old shared an adorable snap of herself in a fitted white dress as Josh could be seen kissing her exposed belly.
“Mini Miller due April 2021,” she captioned with post, alongside a baby and love-heart emoji.
“We are absolutely overjoyed, grateful and love the journey so far.”
The mega influencer, who has an Instagram following of 1.5 million, runs the health and wellness business Keep It Cleaner (KIC) with best friend and fellow model Laura Henshaw.
The duo have a reinvented the online fitness space with their at-home workouts, tips, advice and nutritional programs.
Since posting the exciting news on Wednesday evening, Steph’s post has already amassed nearly 100,000 likes and more than 4,000 comments.
A clearly excited Laura left several “crying” emojis, indicating tears of happiness for her long-time friend and business partner.
Others have bombarded her post leaving messages of congratulations and well wishes.
“BEYOND EXCITED FOR YOU BOTH.. YOU’RE GOING TO MAKE THE BEST PARENTS,” wellness influencer and “meal prep queen” Lady Lolas wrote.
“OH MY GOODNESS. Congratulations Steph and Josh,” another follower added.
“Omfg guys!!!! GUYS!!! I am so excited for you! Congratulations to you both!” wrote a third.
Steph began to gain fame online in 2013 when workout content she posted on Instagram started getting reported by “fitness inspo” Tumblrs and blogs around the world.
Her burgeoning online fanbase is now creeping towards the 2 million follower mark following the success of KIC.
In December last year, the fitness guru tied the knot to childhood sweetheart Josh and wasted no time changing her surname to match his on her Instagram
She shared photos of her stunning wedding with her 1.5 million followers who were in awe of her bridal gown.
She donned a crop top with a full skirt, completely shunning a traditional bridal look to put her killer abs on full display.
Steph’s “dream” dress was designed by One Day Bridal before she changed into a more casual number, teamed with white sneakers.
Both Steph and Josh are overjoyed to be welcoming their first child together early next year.
“Our little family is getting a little bigger soon. We are so excited to meet you little one!” Josh wrote on Instagram, alongside a snap of himself, Steph and their little pup.
National Nonprofit SoldierStrong Announces Donation of 10 iBots to Veterans During VHA Innovation Experience Conference
STAMFORD, Conn., Oct. 28, 2020 (GLOBE NEWSWIRE) — SoldierStrong, a national nonprofit dedicated to helping military veterans take their next steps forward through the use of revolutionary medical technology, is teaming up with renowned inventor Dean Kamen and DEKA Research and Development Corp. to donate 10 iBOT wheelchairs to individual wounded veterans, co-founder and chairman Chris Meek said Tuesday.
“The goal of this donation is to create lasting, life-changing impacts on the physical and mental health of those who have served our country,” said Meek, who made the announcement remotely during the Veterans Health Administration’s Innovation Experience (iEX) conference in Washington, D.C.
The iBOT wheelchair, which is the brainchild of Kamen in partnership with his company, DEKA, and Johnson & Johnson’s Independent Technology division, is a one-of-a-kind powered wheelchair that climbs stairs, allows users to rise from sitting level to six feet tall, maintains superior balance compared to other products on the market and can withstand travel through sand and standing water.
“Dean Kamen is one of the most recognized and sought-after innovators of our time. He’s made it his life’s work to invent technology, like the iBOT, that improves the lives of others,” Meek said. “With such an iconic status in the science and technology communities, it was a tremendous honor to introduce Dean today at the VHA Innovation Experience. It is also with sincerest gratitude that I thank him for his support of SoldierStrong and his commitment to share DEKA’s life-changing iBOT with veterans who desperately deserve access to this type of disruptive technology.”
The VHA Innovation Experience (iEX) is an annual conference that brings innovators and inventors, medical health experts, veterans, and the public together to showcase and celebrate emerging innovations, partnerships and technologies that improve and save veterans’ lives.
Donations of the iBOTs are the latest effort by SoldierStrong to provide revolutionary medical technologies to help injured veterans lead full lives. SoldierStrong has donated $3.8 million in state-of-the-art medical devices to individual veterans and Veterans Affairs medical centers across the country. These devices include hyper-advanced prosthetics, specialized rehabilitation, and the organization’s signature device, the SoldierSuit exoskeleton used in the rehabilitation of spinal injuries and strokes and to help paralyzed individuals become more mobile. To date, SoldierStrong has donated 22 SoldierSuits, or exoskeletons, that allow some paralyzed veterans to stand and walk again.
A four-year mental health study by the VA Eastern Colorado Health Care System that included use of a SoldierSuit found that paralyzed veterans able to maintain an eye-level view of the world experienced better mental and physical health and a decline in suicidal thoughts or attempts.
“This donation of iBOTs allows SoldierStrong to provide technologies that simultaneously address the needs of physical and mental health,” Meek said. “The iBOT’s unique capabilities will allow veterans who receive a donation to feel secure, independent and enjoy a sense of confidence unmatched by other devices.”
CONTACT: CHRISTINA STROBACK
Hours after Lightfoot announces new COVID-19 restrictions, Birx warns during Chicago visit that closing public spaces won’t be enough
CHICAGO — Just hours after Chicago Mayor Lori Lightfoot announced new restrictions on businesses in response to rising COVID-19 cases, White House coronavirus response coordinator Dr. Deborah Birx cautioned that closing public spaces won’t be enough to stop the illness’s spread.
Birx said it’s possible some of the recent spread is happening in people’s homes, during family gatherings, as the weather gets colder. She spoke at a news conference following a private meeting with leaders from Rush University System for Health, Northwestern Medicine and the Illinois and Chicago departments of public health at Northwestern Memorial Hospital on Thursday.
“It won’t be as simple as closing public spaces because public spaces … were very safe over the summer and probably remain safe,” Birx said. “This is really something that has happened in the last three to four weeks. What has happened in the last three to four weeks is that people have moved their social gatherings indoors.”
On Thursday, Mayor Lori Lightfoot announced a curfew for nonessential businesses and no more indoor service at bars that don’t serve food. Illinois Gov. J.B. Pritzker has also announced tighter restrictions on bars, restaurants and gatherings in suburban counties with high COVID-19 positivity rates.
On Thursday the state announced 4,942 new confirmed cases of COVID-19, and the statewide rolling positivity rate stood at 5.7%, up from 3.7% two weeks earlier. In Illinois, 2,463 patients were in the hospital with COVID-19, according to Thursday figures, up from 1,812 two weeks earlier.
Birx also said Thursday that she advocated for weekly testing while meeting privately with hospital and public health leaders.
She said, at the news conference, that finding the “silent cases” and asymptomatic cases is “critical in preventing community spread.”
She recommended asking certain community members — such as community college students, teachers or hospital workers — if they would be willing to be tested weekly. She said universities that have tested students weekly have had more success limiting infections than those that only tested students who had been directly exposed to COVID-19 or had symptoms.
Birx said testing, along with mask-wearing and social distancing, are key to getting the spread of COVID-19 under control.
When asked what she’s doing to get President Donald Trump to understand the importance of social distancing and mask-wearing, she said: “My public health guidance is consistent no matter who I’m speaking to. I think you can see there’s a diversity of how people relate to that message.”
©2020 Chicago Tribune
Visit the Chicago Tribune at www.chicagotribune.com
Distributed by Tribune Content Agency, LLC.
RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows
Dr. James Cook
“As the original designer of the GABAkines licensed by RespireRx, I am very excited to be working on the research team being assembled by RespireRx to realize their therapeutic potential,” said Dr. Cook
Dr. Jeffrey Witkin
“It is an honor to be afforded this singular opportunity to join such a capable and driven team in further progressing the expanding portfolio of highly promising neuromodulator compounds. The broad-ranging efficacy of our GABAkine candidate, KRM-II-81, in preclinical models and in human epileptic tissue, already provides compelling evidence to substantiate this compound as a next-generation antiepileptic drug. I am enthusiastically looking forward to becoming an integral part of RespireRx’ bright future,” said Dr. Witkin.
Glen Rock, N.J., Oct. 27, 2020 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the appointment on October 16, 2020, of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows.
Tim Jones, President and Chief Executive Officer said, ‘‘We are thrilled to formally welcome Dr. Cook and Dr. Witkin to the RespireRx team. In their capacities as Research Fellows, they will immediately assume roles as integral core members of our research team, reporting to Dr. Arnold Lippa, and participate as members of our Scientific Advisory Board. Their intrinsic depth of knowledge, collective academic and industry achievements in the field of neuroscience is unrivaled. Their expertise in the development of novel and innovative glutamate and GABA-A receptor neuromodulators, across a broad scope of patient -critical disorders will prove extremely valuable as we continue to grow the business; in parallel, we are actively expanding our portfolio of products, broadening our technical and regulatory asset base and in turn strengthening our already longstanding collaboration with the University of Wisconsin-Milwaukee Research Foundation ‘UWMRF’.’
Dr. James Cook is a Distinguished Professor of Chemistry at the University Wisconsin-Milwaukee where he co-leads a group of scientists who have synthesized and tested a broad series of novel drugs that display GABA-A receptor subtype selectivity and pharmacological specificity. He is a leading expert in GABA-A receptor drug targeting with more than 40 years’ experience in organic and medicinal chemistry and more than 500 scientific publications and 60 patents.
Dr. Jeffrey Witkin, is
Fit4Mii app Announces Online and Online-to-offline Fitness Training Platform and Multi-Lingual Marketplace
“Find the right fit for you at Fit4Mii”
In one swift move, Fit4Mii app has established a workout system that allows fitness enthusiasts to participate virtually via the internet or offline from it’s world-class trainers. The platform also features a marketplace where fitness enthusiasts can get their hands on all necessary tools required to achieve a healthy body and mind.
Fit4Mii app is a fully accessible online and online-to-offline fitness platform and market place. It provides online training for everyone, no matter age or ability both on and offline. Fit4Mii app trainers go through rigorous training and are largely multi-lingual and when combined, speak 19 languages. They are qualified in many disciplines including Muay Thai, corrective exercise, yoga, nutrition, pilates, and Zumba. At Fit4Mii app, there is an online fitness class for everyone, everywhere regardless of age, language, health condition, body type and gender.
Given the covid pandemic, health and fitness has become an important focus. Physical fitness is generally achieved through proper nutrition, moderate to vigorous physical exercise, and sufficient rest. The Fit4Mii app online fitness platform does not only help users to exercise, but to do it the right way. Fit4Mii app enables each participant to find tailored fitness programs to help them get the most from working out. Besides fitness, these programs also touch on other aspects of health and wellness such as bone, mental, social and emotional.
Fit4Mii app has a well-rounded online fitness program to improve a person’s fitness levels in all aspects of fitness. Fitness enthusiasts have come forward to say that the platform has been a lot of help as it has pushed them into developing other parts of their bodies. Without Fit4Mii app, most participants confessed to only practicing cardio/respiratory endurance or weight training.
Fit4Mii app is virtual gym providing live and interactive fitness classes online. Participants can access several fitness courses or programs ranging from Cardio, Dance, Nutrition to Kids fitness, and Family. In a bid to make its services available to everyone, the team at Fit4Mii has made sure to mix its paid courses with some free courses. Now, everyone can participate.
For more information visit the Fit4Mii website or use the media contact outlets below.
Company Name: Fit4Mii app
Contact Person: C.king
Email: Send Email
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Fit4Mii app Announces Online and Online-to-offline Fitness Training Platform and Multi-Lingual Marketplace
Intermountain Healthcare CEO Marc Harrison and Sanford Health CEO Kelby Krabbenhoft announced a merger on Monday in Sioux Falls. (Photo: Gabrielle Pike)
Sanford Health CEO Kelby Krabbenhoft announced Monday that Sanford is planning to merge with Intermountain Health, a Salt Lake City based health system and Utah’s largest private employer.
The alliance shifts top leadership to Intermountain Health, as Krabbenhoft serves as president emeritus and Dr. Marc Harrison, president and CEO of Intermountain, serves as president and CEO. Headquarters will also move to Utah while corporate offices will be in Sioux Falls.
The merger creates a sprawling $15 billion health system whose service area spans the western United States and Upper Midwest. Besides health care, both entities operate a private health insurance business, and Sanford also owns the Evangelical Lutheran Good Samaritan Society.
Both organizations will keep their current names for the “foreseeable future.” The parent company will be Intermountain Healthcare.
‘A match made in heaven’
The organizations plan to officially combine by summer 2021, pending regulatory approvals. Harrison and Krabbenhoft started discussing the merger after meeting in April. Krabbenhoft said he was introduced to Harrison by Utah Gov. Mike Leavitt while on a business trip to Salt Lake City.
“In many ways this is a match made in heaven,” Harrison said during Monday’s announcement.
On paper, the two systems are similar. Intermountain operates 24 hospitals and 215 clinics in Utah, Nevada and Idaho. The system employs 41,700 people, including 2,971 physicians and advanced-practice providers.
Sanford employs 47,757 at its 46 medical centers and 210 clinics. Of those, 2,633 are physicians or advanced-practice providers. Sanford is South Dakota’s largest private employer.
Both systems operate large hospitals in their metropolitan service areas as well as operate in rural settings. The combined organization will employ more than 89,000 people and operate 70 hospitals.
“You get a cultural match that really is quite powerful,” Krabbenhoft said.
“This is two really strong organizations coming together,” Harrison said. “It’s not me sending a check to Kelby, and it’s not him sending one to me.”
But where the two organizations differ is in the strength of their private health insurance businesses, Krabbenhoft said. Intermountain’s health insurance business, SelectHealth, has more than 900,000 members and about $4 billion in revenue. The Sanford Health Plan has about 210,000 members and about $1 billion in revenue.
Krabbenhoft said that Sanford has been stymied over the years in its efforts to build up a stronger insurance pool and that the merger “really solves a problem for us.”
“It’s just a scale issue,” he said.
Sanford Health has history of expansion
Monday’s announcement confirmed rumors that had been swirling for weeks in Sioux Falls, and it marks another chapter in Sanford’s drive to expand, which included the system’s merger with the Good Samaritan Society in 2018. A decade ago, Sanford merged with North Dakota-based MeritCare, which deepened its reach into the Upper
Trudeau challenges Trump’s claim that vaccine will be available ‘in weeks’, announces $214M for Canadian vaccine development
For more on today’s top stories and the spread of the novel coronavirus across the country, please refer to our live updates below throughout the day, as well as our COVID-19 news hub.
Trudeau says COVID-19 vaccine won’t come before the new year
At a press conference on Friday, Prime Minister Justin Trudeau responded to U.S. President’s Donald Trump’s claim that a viable COVID-19 vaccine could be available in a matter of “weeks,” if not by the end of the year.
“We are hopeful that the vaccines will arrive yesterday, but they won’t,” Trudeau said. “There’s still a number more months of work to do.”
“Reasonable expectation is that vaccines could start to arrive sometime in the new year but even then, there will be smaller amounts of doses that will have to be distributed to priority populations, I think of most vulnerable or our frontline workers.”
The prime minister also said Canada has “an excellent portfolio of vaccine potentials” but stressed that “nobody’s got a vaccine yet.”
“There are still trials going on, there are still a number of companies, some closer than others, but we are waiting to ensure that those vaccines are effective and further, that they will be safe for Canadians,’ Trudeau said. “Nothing will be distributed in Canada until Health Canada is absolutely certain that the safety of Canadians is being properly covered and taken care of.”
PM looking at Alberta travel pilot project to guide loosening border restriction
The prime minister also commented on yesterday’s announcement that Alberta will begin a pilot project in November, allowing travellers to be tested for COVID-19 upon returning to the province to reduce the required self-isolation time
“We’re interested in seeing the result of this pilot project, but it is only a pilot project,” Trudeau said. “As we move forward into the coming months and perhaps look at loosening some of the border restrictions internationally, we will be able to have data to rely on to make sure that we are first and foremost, keeping Canadian’s safe and controlling the spread of the virus.”
‘This is serious’
When speaking more generally about the COVID-19 situation in Canada, the prime minister stressed to Canadians that the daily case numbers in the country need to be reduced, as Canada saw its highest single-day increase on Thursday, totalling 2,786 cases.
“We have to get these numbers down, this is serious and everybody must do their part,” Trudeau said. “People’s lives are at stake, we can’t afford to be careless or think that this virus will just go away on its own.”
Dr. Theresa Tam, Canada’s chief public health officer, spoke specifically about the increases in outbreaks in long-term care facilities in Canada, including Ontario and Quebec.
“The size of the outbreaks are smaller than in the initial wave,” Dr. Tam identified. “I’m not sure exactly what that means, that could be people are identifying things more rapidly and putting in control measures, and the prevention is better, but
Relievant Announces Positive 12-Month Intracept Effectiveness Study Results From Community Based Practices
MINNEAPOLIS, Oct. 22, 2020 (GLOBE NEWSWIRE) — Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced the North American Spine Society Journal publicationi of results from an effectiveness study showing that the significant improvements in function and pain initially reported at an interim analysis of three monthsii following the Intracept Procedure remained significant through one year.
The prospective, open-label, single-arm study followed 47 patients treated with the Intracept procedure for chronic low back pain through 12 months at two community-based practices – led by Kevin Macadaeg, MD at Indiana Spine Group and Eeric Truumees, MD at Ascension Texas Spine and Scoliosis Center. Inclusion criteria were more permissive than those employed in the previously-reported SMART and INTRACEPT randomized controlled trials (RCT’s), including patients having undergone prior discectomy and utilizing extended-release narcotics, reflective of patients found in “real world” spine and pain practices versus previous highly controlled study protocols.
Results 12-months post-procedure included the following:
Mean ODI improvement of 32.31 (p<0.001) from a baseline of 46.98 (more than twice the established minimal clinically important difference (MCID) of 15)
Mean VAS reduction of 4.31 (p<0.001) from a baseline of 6.82 (more than twice the established MCID of 2)
69% of patients reported >50% reduction in pain while 38% reported being pain free
70% of the patients who were using opioids at baseline were no longer actively using opioids at 12 months (> 1 time per week)
96% of the patients who had injections prior to treatment did not have any injections in the 12 months after treatment
84.4% of patients rated their condition as improved (60% vastly improved) and 89% indicated they would have the procedure again
“Previous, highly-controlled studies have shown the positive outcomes achieved following the Intracept procedure are both significant and durable,” said Kevin Macadaeg, MD, Minimally Invasive Spine Specialist at Indiana Spine Group and the principal investigator of the study, “This study demonstrates that patients treated in a typical spine practice can achieve similar outcomes a year post-procedure as those previously reported – meaningful improvements in function and pain that reduce healthcare utilization and improve patient satisfaction.”
“It’s important for physicians to know that patients in their own practice can achieve similar improvements as those reported in the significant body of evidence supporting the Intracept procedure – including two Level I RCTs and a long-term, 5-year study,” said Art Taylor, President & CEO of Relievant Medsystems. “This evidence further indicates that the effectiveness and strong safety profile of the Intracept procedure can be achieved at typical spine practices, bringing relief to vertebrogenic CLBP patients who have often suffered from their condition for years. Physicians, payers, and most of all, CLBP patients are excited by the unparalleled level of evidence supporting the Intracept procedure in this difficult-to-treat population.”
The publication is currently available via open access and can be found at the following link: https://doi.org/10.1016/j.xnsj.2020.100030
About Relievant Medsystems
Relievant Medsystems is a privately-held medical device company that
Pfizer to develop ARX-1796 which, if approved, has potential to be the first novel oral beta-lactamase inhibitor + antibiotic combination in more than 35 years
Arixa Pharmaceuticals™, Inc., a company dedicated to developing next-generation oral antibiotics for drug-resistant Gram-negative infections today announced that Pfizer’s Hospital Business has agreed to acquire Arixa.
Arixa’s lead compound, ARX-1796, is an oral prodrug of avibactam, a beta lactamase inhibitor (BLI) that was FDA-approved in 2015 as part of Avycaz® (sold by Pfizer as Zaficefta® outside the United States), an intravenous-only combination with ceftazidime for the treatment of a number of indications caused by Gram-negative pathogens. Arixa Co-Founder and CSO Dr. Eric M. Gordon led a team to address the challenge of creating a viable prodrug of avibactam with now-patented chemistry. As a result of Arixa’s now patented chemistry, the prodrug of avibactam was 60-80% absorbed when administered orally to humans in a Phase 1 clinical trial, releasing the FDA-approved avibactam molecule in the bloodstream. In contrast, ~7% of the intravenous compound is absorbed orally.i Combined with an antibiotic such as ceftibuten, Arixa’s ARX-1796, if approved, opens the way for orally-available avibactam to be part of a next-generation, oral antibiotic combination for resistant urinary tract and other infections.
“We are proud to have created and developed an important new drug candidate in a highly capital efficient manner, and believe Pfizer is the perfect company to take ARX-1796 into subsequent clinical trials and if approved, eventually to patients in need,” said John G. Freund MD MBA, Co-Founder and CEO, Arixa. “We built Arixa as a completely virtual company, with no employees and essentially no overhead – our work was performed by Contract Research Organizations under the supervision of a group of part-time expert consultants. This model has been behind the success of driving the developmental course of ARX-1796.”
“Through this acquisition, Pfizer will advance the development program for Arixa’s leading asset, ARX-1796. We are excited by the potential benefits ARX-1796 may provide to patients and the healthcare system overall, potentially allowing patients to leave the hospital earlier or avoid the need for hospital admission altogether,” said Annaliesa Anderson, Vice President and Chief Scientific Officer Bacterial Vaccines and Hospital, Pfizer.
“Beta-lactamase inhibitor combinations have become a mainstay of antimicrobial therapy, but clavulanic acid, approved by FDA in 1984, is the only inhibitor available to treat patients that is orally bioavailable,” said Karen Bush, Ph.D., an expert in beta-lactamase resistance and Professor of Practice, Biotechnology at Indiana University – Bloomington. Clavulanic acid is the BLI in Augmentin® (amoxicillin-clavulanic acid). “Avibactam has much broader coverage than clavulanic acid against beta lactamase enzymes that bacteria make to defend themselves against antibiotics such as penicillins, cephalosporins and carbapenems,” Dr. Bush said.
“Common Gram-negative infections such as complicated urinary tract infections are becoming a major treatment challenge because of increasing rates of multidrug resistance,” said Jose Vazquez, M.D., Professor, Department of Medicine and Chief of Infectious Diseases at Medical College of Georgia at Augusta University. “There are a progressively
Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients
Roche and Atea partner to jointly develop AT-527, an orally administered direct-acting antiviral (DAA) currently in Phase 2 clinical trials
AT-527 has the potential to be the first novel oral antiviral to treat COVID-19 patients outside the hospital setting as well as in the hospital and may also be used in post-exposure prophylactic settings
Oral, small-molecule DAAs for COVID-19 patients allow for large-scale manufacturing and facilitate broad patient access
If approved, Atea will distribute AT-527 in the United States and Roche will be responsible for global manufacturing and distribution outside the United States
Basel, 22 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Atea Pharmaceuticals, Inc. announced today that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT-527, Atea’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication, and is currently being studied in a Phase 2 clinical trial for hospitalised patients with moderate COVID-19. A Phase 3 clinical trial, expected to start in Q1 2021, will explore the potential use in patients outside of the hospital setting. In addition, AT-527 may be developed for post-exposure prophylactic settings.
AT-527, while being a potential oral treatment option for hospitalised patients, also holds the potential to be the first oral treatment option for COVID-19 patients that are not hospitalised. Additionally, the manufacturing process of small-molecule DAAs allows the ability to produce large quantities of a much needed treatment. If successful, AT-527 could help treat patients early, reduce the progression of the infection, and contribute to decreasing the overall burden on health systems.
The collaboration aims to accelerate the clinical development and manufacturing of AT-527, to investigate its safety and efficacy, and to provide this potential treatment option to patients around the world as quickly as possible. If AT-527 proves safe and effective in clinical trials and regulatory approvals are granted, Atea will be responsible for distributing this treatment option in the U.S, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the United States.
“The ongoing complexities of COVID-19 require multiple lines of defence. By joining forces with Atea, we hope to offer an additional treatment option for hospitalised and non-hospitalised COVID-19 patients, and to ease the burden on hospitals during a global pandemic.” said Bill Anderson, Chief Executive Officer of Roche Pharmaceuticals. “In jointly developing and manufacturing AT-527 at scale, we seek to make this treatment option available to as many people around the world as we possibly can.”
“Roche shares our passion for delivering innovative new medicines to address great unmet medical needs. The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea Pharmaceuticals. “AT-527 is expected to be ideally suited to combat COVID-19 as it inhibits viral replication by interfering with viral RNA polymerase, a key component in the